Qiagen NV (QGEN) Falls to 7-Year Low as MidEast Tensions Drag Q1

Qiagen NV (NYSE:QGEN) is one of the 10 Stocks Reeling From Huge Losses.

Shares of Qiagen nosedived to a seven-year low on Tuesday, slashing 10.7 percent to close at $34.02 apiece, as investors soured on its lower growth outlook for the year following the impact of tensions in the Middle East.

In its preliminary results, Qiagen NV (NYSE:QGEN) said that it expects to report preliminary net sales of $492 million, up 2 percent on a reported basis and down 1 percent at constant exchange rates (CER) as compared with the 1 percent a year earlier.

Photo by Tima Miroshnichenko on Pexels

Across its business, the company said that sales from its QuantiFERON blood test kit have dropped amid the decline in immigration testing demand in the US and the Middle East. Sales from QIAstat-Dx diagnostics also dipped 1 percent, as expected, amid tough results last year.

Following the trends, Qiagen NV (NYSE:QGEN) lowered its net sales growth outlook for full-year 2026 to a range of 1 to 2 percent, versus 5 percent previously, amid the lingering uncertainties in the Middle East. Adjusted EPS was also decreased to $2.43 from $2.50 prior.

For the second quarter alone, Qiagen NV (NYSE:QGEN) expects net sales to decline by 2 percent from $534 million in the same period a year earlier. Adjusted diluted EPS is targeted at $0.60, flat from the comparable period.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.